In a report released yesterday, Yatin Suneja from Guggenheim maintained a Hold rating on ACADIA Pharmaceuticals (ACAD – Research Report), with a price target of $20.00. The company’s shares closed yesterday at $19.34.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Suneja covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals, Axsome Therapeutics, and Immunovant. According to TipRanks, Suneja has an average return of 4.2% and a 43.94% success rate on recommended stocks.
In addition to Guggenheim, ACADIA Pharmaceuticals also received a Hold from Bank of America Securities’s Tazeen Ahmad in a report issued yesterday. However, on the same day, JMP Securities reiterated a Buy rating on ACADIA Pharmaceuticals (NASDAQ: ACAD).
The company has a one-year high of $24.53 and a one-year low of $14.15. Currently, ACADIA Pharmaceuticals has an average volume of 2.55M.
Read More on ACAD:
- ACADIA Pharmaceuticals Reports Strong Earnings and Growth Plans
- Positive Outlook for ACADIA Pharmaceuticals Driven by Strong Daybue Sales and Promising Pipeline
- Acadia Pharmaceuticals price target lowered to $37 from $39 at Citizens JMP
- Positive Outlook for ACADIA Pharmaceuticals: Strategic Growth and Promising Metrics Drive Buy Rating
- Optimistic Growth Outlook for ACADIA Pharmaceuticals: Buy Rating Affirmed by Tessa Romero
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue